Paragraph 6 End-stage kidney disease requiring renal replacement therapyI1

United Kingdom

A person (“P”) is to be treated as having end-stage kidney disease requiring renal replacement therapy if they have required renal replacement therapy for at least 3 months as a result of—

(a)

where P has HIV, any of the following conditions—

(i)

HIV-associated nephropathy;

(ii)

HIV-associated immune complex chronic kidney disease;

(iii)

drug associated kidney disease in conjunction with treatment with foscarnet F1sodium, cidofovir or tenofovir disoproxil;

(b)

where P has a Hepatitis B infection of severity level 2, 3 or 4, any of the following conditions—

(i)

membranous nephropathy;

(ii)

membranoproliferative glomerulonephritis including in the presence of mixed cryoglobulinaemic vasculitis;

(iii)

IgA nephropathy;

(iv)

tenofovir-induced renal failure;

(c)

where P has a Hepatitis C infection of severity level 2, 3 or 4, membranoproliferative glomerulonephritis mainly in the presence of mixed cryoglobulinaemic vasculitis.

Annotations

Textual amendments

F1: Word in Sch. 2 para. 6(a)(iii) substituted (31.12.2025) by The Infected Blood Compensation Scheme (Amendment) Regulations 2025 (S.I. 2025/1358), regs. 1(2), 14(11)

Commencement

I1: Sch. 2 para. 6 in force at 31.3.2025, see reg. 1(2)